X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ACTAVIS (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   ACTAVIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ACTAVIS
Dec-18
SUN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs70113,493-   
Low Rs4339,051-   
Sales per share (Unadj.) Rs110.43,309.8-  
Earnings per share (Unadj.) Rs11.0-1,066.1-  
Cash flow per share (Unadj.) Rs17.2348.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.813,651.2-  
Shares outstanding (eoy) m2,399.26332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 150.8%   
Avg P/E ratio x51.6-10.6 -488.4%  
P/CF ratio (eoy) x32.932.3 101.8%  
Price / Book Value ratio x3.60.8 432.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0213,749,019 36.3%   
No. of employees `00017.816.9 105.3%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.965,137.7 22.9%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.6-20,980.9 -7.1%   
INCOME DATA
Net Sales Rs m264,8951,100,828 24.1%  
Other income Rs m8,38821,051 39.8%   
Total revenues Rs m273,2821,121,879 24.4%   
Gross profit Rs m56,08128,847 194.4%  
Depreciation Rs m14,998470,580 3.2%   
Interest Rs m5,17663,524 8.1%   
Profit before tax Rs m44,295-484,205 -9.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505123,492 -7.7%   
Tax Rs m8,452-6,136 -137.7%   
Profit after tax Rs m26,338-354,577 -7.4%  
Gross profit margin %21.22.6 807.9%  
Effective tax rate %19.11.3 1,505.7%   
Net profit margin %9.9-32.2 -30.9%  
BALANCE SHEET DATA
Current assets Rs m316,359451,502 70.1%   
Current liabilities Rs m198,643399,413 49.7%   
Net working cap to sales %44.44.7 939.2%  
Current ratio x1.61.1 140.9%  
Inventory Days Days9520 484.1%  
Debtors Days Days10866 162.4%  
Net fixed assets Rs m213,178124,608 171.1%   
Share capital Rs m2,3990-   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,0064,540,399 8.4%   
Long term debt Rs m17,7211,598,839 1.1%   
Total assets Rs m643,0287,097,677 9.1%  
Interest coverage x9.6-6.6 -144.3%   
Debt to equity ratio x00.4 13.2%  
Sales to assets ratio x0.40.2 265.6%   
Return on assets %4.9-4.1 -119.5%  
Return on equity %6.9-7.8 -88.5%  
Return on capital %10.0-4.8 -207.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,072393,284 9.9%  
From Investments Rs m-33,708216,058 -15.6%  
From Financial Activity Rs m-15,393-674,993 2.3%  
Net Cashflow Rs m-7,359-65,323 11.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.73 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: DR. DATSONS LABS  TORRENT PHARMA  PANACEA BIOTECH  VENUS REMEDIES  BIOCON   



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views On News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 14, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS